Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio di GS-0201 da solo e in combinazione in partecipanti con tumori solidi avanzati

10 novembre 2026 aggiornato da: Gilead Sciences

Uno studio di fase 1 per valutare la sicurezza e la tollerabilità di GS-0201 in monoterapia e in combinazione negli adulti con tumori solidi avanzati

The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-0201 when given alone or in combination with sacituzumab govitecan (SG) in participants with advanced solid tumors.

The primary objectives of this study are to:

  • To assess the safety and tolerability of GS-0201 as monotherapy and in combination with SG in participants with selected advanced solid tumors
  • To identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of GS-0201 as monotherapy and the MTD and/or the RP2D and dosing schedule of GS-0201 in combination with SG in participants with selected advanced solid tumors

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

278

Fase

  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Gangnam-Gu, Corea del Sud, 06351
        • Reclutamento
        • Samsung Medical Center
      • Goyang-si Gyeonggi-do, Corea del Sud, 10408
        • Reclutamento
        • National Cancer Center - Korea
      • Seoul, Corea del Sud, 05505
        • Reclutamento
        • Asan Medical Center
      • Seoul, Corea del Sud, 03722
        • Reclutamento
        • Yonsei University Severance Hospital
      • Seoul, Corea del Sud, 03080
        • Reclutamento
        • Samsung Medical Center
      • Haifa, Israele, 31096
        • Reclutamento
        • Rambam Health Care Campus
      • Jerusalem, Israele, 9112001
        • Reclutamento
        • Hadassah Medical Center
      • Tel Aviv, Israele, 6423906
        • Reclutamento
        • Tel Aviv Sourasky Medical Center
      • Tel HaShomer, Israele, 52621
        • Reclutamento
        • Chaim Sheba Medical Center
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02459
        • Reclutamento
        • Dana-Farber Cancer Institute
    • New York
      • New York, New York, Stati Uniti, 10065
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center
    • Texas
      • Austin, Texas, Stati Uniti, 78758
        • Reclutamento
        • NEXT Austin
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • The University of Texas MD Anderson Cancer Center
      • Irving, Texas, Stati Uniti, 75039
        • Reclutamento
        • NEXT Dallas

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Able to understand and give written informed consent.

  • Assigned female or male at birth, 18 years of age or older, and meet the age of majority/adulthood per local regulations.

  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.

  • Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria by investigator assessment.

  • Organ function requirements:

    • Adequate hematologic function
    • Adequate hepatic function
    • Creatinine clearance
    • Coagulation
  • Tissue requirement:

    • Parts A, B, C, and D:

      • Pre-treatment tumor tissue is required.
    • Parts A and C backfill biopsy cohorts:

      • Individuals must agree to fresh pre- and on-treatment biopsies.
  • Individuals assigned male at birth and individuals assigned female at birth and of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception

  • Willing and able to comply with the requirements and restrictions in this protocol

  • Part A (GS-0201 Monotherapy Dose Escalation) Inclusion Criteria:

    • Histologically/cytologically confirmed progressive/advanced solid tumors with selected molecular lesions.
    • Individuals must have received, been intolerant to, or been ineligible for all treatment known to confer clinical benefit or have a contraindication to receive the therapy
  • Part B (Dose Expansion) Inclusion Criteria:

    • Disease documented as:

    • Cohort B1:

      • Histologically or cytologically confirmed progressive/advanced selected solid tumor diagnoses harboring defined molecular lesions
      • Participants may potentially be required to forgo treatment with approved agent(s) to be able to participate in the study
    • Cohort B2:

      • Histologically or cytologically confirmed progressive/advanced solid tumor diagnoses harboring defined molecular lesions not included in Cohort B1
  • Part C (Dose Escalation) Inclusion Criteria:

    • Histologically or cytologically confirmed unresectable locally advanced/metastatic selected solid tumors
  • Part D (Dose Expansion) Inclusion Criteria:

    • Disease documented as:

    • Cohort D1:

      • Histologically or cytologically confirmed unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC)
    • Cohort D2:

      • Recurrent/persistent endometrial cancer

Exclusion Criteria:

  • Pregnant or lactating females

  • Known hypersensitivity to any of the study drugs, its metabolites, or formulation excipients

  • Requirement for ongoing therapy with or use of any prohibited medications described in the protocol

  • Individuals with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with findings suggestive of MDS/AML

  • Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of GS-0201

  • The therapies listed below within the specified timeframe:

    • Major surgery (excluding minor procedures, eg, placement of vascular access, gastrointestinal/biliary stent, biopsy) < 4 weeks prior to planned Cycle 1 Day 1
    • Immunotherapy or biologic therapy < 21 days prior to planned Cycle 1 Day 1
    • Chemotherapy < 14 days prior to planned Cycle 1 Day 1, or < 42 days for mitomycin or nitrosoureas
    • Targeted small molecule therapy < 14 days prior to planned Cycle 1 Day 1
    • Receipt of experimental therapy within 21 days or 5 experimental treatment half-lives (whichever is longer) prior to planned Cycle 1 Day 1
    • Hormonal or other adjunctive therapy for cancers other than the cancer under evaluation in this study that started < 14 days prior to planned Cycle 1 Day 1 are not permitted. Hormonal therapy, bisphosphonates, somatostatin analogues, and leuprolide are permitted if started ≥ 14 days prior to planned Cycle 1 Day 1
    • Radiotherapy within 2 weeks prior to planned Cycle 1 Day 1 and the radiation is not administered to a target lesion
    • Any prior allogeneic tissue/solid organ transplantation, including allogeneic hematopoietic stem cell transplantation. Individuals with a history of autologous hematopoietic stem cell transplantation are also excluded
  • Have not recovered (ie, Grade 1 or lower) from AEs due to a previously administered agent

  • Prior treatment with approved or experimental prohibited agents as detailed in the protocol.

  • Diagnosis of immunodeficiency, either primary or acquired, or requires systemic corticosteroids (> 10 mg of prednisone daily, or equivalent). However, replacement doses, topical, ophthalmologic, and inhalational steroids are permitted

  • Have an active second malignancy

  • Have known active central nervous system (CNS) metastases

  • Individuals with carcinomatous meningitis or primary CNS tumors are excluded regardless of clinical stability

  • Meet any of the following criteria for cardiac disease:

    • Myocardial infarction or unstable angina pectoris within 6 months of enrollment
    • History of serious ventricular arrhythmia (ie, ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication)
    • QT interval > 470 msec
    • New York Heart Association Class III or greater congestive heart failure or known left ventricular ejection fraction less than 40%
  • Meet any of the following infectious criteria:

    • Have active serious infection requiring antimicrobials
    • Have active hepatitis B virus (HBV) or hepatitis C virus (HCV), or HIV. In individuals with a history of HBV or HCV, individuals with detectable viral loads will be excluded
    • Individuals who test positive for hepatitis B surface antigen. Individuals who test positive for hepatitis B core antibody are eligible with a negative HBV DNA by quantitative Polymerase chain reaction (PCR)
    • Individuals who test positive for HCV antibody. Individuals who test positive for HCV antibody are eligible with a negative HCV RNA by quantitative PCR
    • Individuals who test positive for HIV antibody
  • History of pneumonitis requiring treatment with corticosteroids, interstitial lung disease, or radiation pneumonitis requiring steroids

  • Symptomatic ascites or pleural effusion

  • Have other concurrent medical or psychiatric conditions that, in the investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations

  • Any medical condition that, in the investigator's or sponsor's opinion, poses an undue risk to the individuals participation in the study

  • Use of any live vaccines against infectious diseases within 4 weeks (28 days) of initiation of study drug(s) (inactivated, viral vector vaccines, and messenger RNA (mRNA) vaccines are allowed; seasonal vaccines should be up to date prior to planned Cycle 1 Day 1)

  • Parts C (Dose Escalation) and D (Dose Expansion): Combination Cohorts:

    • Individuals with active chronic inflammatory bowel disease (ulcerative colitis, Crohn disease) and individuals with a history of bowel obstruction or gastrointestinal perforation within 6 months prior to planned Cycle 1 Day 1
    • Individuals who previously received topoisomerase 1 inhibitors or antibody-drug conjugates containing a topoisomerase 1 inhibitor
    • Known severe intolerance or life-threatening hypersensitivity reactions to humanized monoclonal antibodies or intravenous (IV) immunoglobulin preparations; any history of anaphylaxis; history of human anti-human antibody response

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Part A: GS-0201 Monotherapy Dose Escalation

Participants will receive escalating doses of GS-0201 monotherapy, until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol or up to 105 weeks, whichever occurs first.

Pill administered orally

Sperimentale: Part B: Cohort B1: GS-0201 Monotherapy Dose Expansion

Participants with selected breast cancer indication will receive GS-0201 monotherapy at the recommended dose for expansion.

Pill administered orally

Sperimentale: Part B: Cohort B2: GS-0201 Monotherapy Dose Expansion

Participants with selected indications not included in cohort B1 will receive GS-0201 monotherapy at the recommended dose for expansion.

Pill administered orally

Sperimentale: Part C: Dose Escalation: GS-0201 + Sacituzumab Govitecan (SG)

Participants will receive escalating doses of GS-0201 in combination with SG, until disease progression, or until the participant meets other study drug discontinuation criteria as specified in protocol or up to 105 weeks, whichever occurs first.

Pill administered orally

Administered intravenously

Altri nomi:
  • IMMU-132
  • GS-0132
  • Trodelvy®
Sperimentale: Part D: Cohort D1: Dose Expansion: GS-0201 + SG

Participants with confirmed unresectable locally advanced or metastatic triple negative breast cancer (mTNBC) will receive GS-0201 at the recommended Phase 2 dose (RP2D) in combination with SG.

Pill administered orally

Administered intravenously

Altri nomi:
  • IMMU-132
  • GS-0132
  • Trodelvy®
Sperimentale: Part D: Cohort D2: Dose Expansion: GS-0201 + SG

Participants with recurrent/persistent endometrial cancer will receive GS-0201 at the recommended Phase 2 dose (RP2D) in combination with SG.

Pill administered orally

Administered intravenously

Altri nomi:
  • IMMU-132
  • GS-0132
  • Trodelvy®

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
La percentuale di partecipanti con eventi avversi (EA) ed eventi avversi gravi (SAE)
Lasso di tempo: Prima dose fino a 30 giorni dopo l’ultima dose (fino a circa 109 settimane).
Prima dose fino a 30 giorni dopo l’ultima dose (fino a circa 109 settimane).
L'incidenza delle anomalie di laboratorio
Lasso di tempo: Prima dose fino a 30 giorni dopo l’ultima dose (fino a circa 109 settimane).
Prima dose fino a 30 giorni dopo l’ultima dose (fino a circa 109 settimane).
The Number of Participants with Dose Limiting Toxicities (DLTs) During Dose Escalation
Lasso di tempo: First dose up to 30 days post last dose (Up to approximately 109 weeks).

DLTs are defined as any of the following treatment-emergent adverse events (AEs) regardless of attribution (graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0), unless clearly related to an underlying disease or extraneous causes, with onset within the DLT-evaluation period for the corresponding dose.

First dose up to 30 days post last dose (Up to approximately 109 weeks).

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
GS-0201 Concentrazioni plasmatiche
Lasso di tempo: Pre-dose e post-dose fino alla fine del trattamento (fino a 105 settimane)
Pre-dose e post-dose fino alla fine del trattamento (fino a 105 settimane)
Concentrazioni sieriche di sacituzumab Govitecan (SG) (solo Parti C e D)
Lasso di tempo: Pre-dose e post-dose fino alla fine del trattamento (fino a 105 settimane)
Pre-dose e post-dose fino alla fine del trattamento (fino a 105 settimane)
Pharmacokinetic (PK) Parameter: Area Under the Concentration (AUC)0-24 of GS-0201
Lasso di tempo: Predose and postdose up to end of treatment (up to 105 weeks)

AUC0-24 is defined as the concentration of drug over time between time 0 and time 24 hours.

Predose and postdose up to end of treatment (up to 105 weeks)
PK Parameter: Cmax of GS-0201
Lasso di tempo: Predose and postdose up to end of treatment (up to 105 weeks)

Cmax is defined as the maximum observed drug concentration.

Predose and postdose up to end of treatment (up to 105 weeks)
PK Parameter: Tmax of GS-0201
Lasso di tempo: Predose and postdose up to end of treatment (up to 105 weeks)

Tmax is defined as the time to maximum observed concentration.

Predose and postdose up to end of treatment (up to 105 weeks)
PK Parameter: AUC0-168 of SG (Parts C and D only)
Lasso di tempo: Predose and postdose up to end of treatment (up to 105 weeks)

AUC0-168 is defined as the concentration of drug over time between time 0 and time 168 hours.

Predose and postdose up to end of treatment (up to 105 weeks)
PK Parameter: Cmax of SG (Parts C and D only)
Lasso di tempo: Predose and postdose up to end of treatment (up to 105 weeks)

Cmax is defined as the maximum observed drug concentration.

Predose and postdose up to end of treatment (up to 105 weeks)
PK Parameter: Tmax of SG (Parts C and D only)
Lasso di tempo: Predose and postdose up to end of treatment (up to 105 weeks)

Tmax is defined as the time to maximum observed concentration.

Predose and postdose up to end of treatment (up to 105 weeks)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Gilead Study Director, Gilead Sciences

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

9 gennaio 2024

Completamento primario (Stimato)

1 settembre 2028

Completamento dello studio (Stimato)

1 settembre 2028

Date di iscrizione allo studio

Primo inviato

4 dicembre 2023

Primo inviato che soddisfa i criteri di controllo qualità

4 dicembre 2023

Primo Inserito (Effettivo)

12 dicembre 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • GS-US-686-6854

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .